Showing 3711-3720 of 6978 results for "".
- NEA Study Illuminates Gaps in Mental Health Help for Eczema Patientshttps://practicaldermatology.com/news/nea-study-illuminates-gaps-mental-health-help-eczema-patients/2467195/Forty-two percent of patients with atopic dermatitis (eczema) and caregivers of children/teens with the condition never spoke about mental health with primary eczema care providers, according to National Eczema Association (NEA
- POSITIVE: Tildrakizumab Shows Effectiveness in Psoriasis Patients at 52 Weekshttps://practicaldermatology.com/news/positive-tildrakizumab-shows-effectiveness-psoriasis-patients-52-weeks/2467194/New one-year data presented at the International Federation of Psoriasis Associations (IFPA) Conference 2024 showed that tildrakizumab (Illumetri, Almirall) was effective at restoring and maintaining wellbeing of patients with moderate-to-severe psoriasis. Researchers for the POSITIVE st
- Erenumab Associated with Reduced Rosacea-associated Flushing, Chronic Erythemahttps://practicaldermatology.com/news/erenumab-associated-reduced-rosacea-associated-flushing-chronic-erythema/2467166/Erenumab, an anti–calcitonin gene-related peptide (CGRP)-receptor monoclonal antibody, was shown in new research to be effective at reducing the number of days with rosacea-associated erythema and flushing in treated patients.
- Biofrontera Unveils New Red-Light-Emitting Lamp for PDT on Actinic Keratoseshttps://practicaldermatology.com/news/biofronters-unveils-new-red-light-emitting-lamp-pdt-actinic-keratoses/2467140/Biofrontera Inc. announced the launch of the RhodoLED XL, a new red-light-emitting LED lamp approved by the US Food and Drug Administration (FDA) in combination with Ameluz (aminolevulinic acid hydrochloride) topical gel, 10% for photodynamic therapy of actinic keratoses of mild-to-moderate sever
- Link Between UV Exposure and Cutaneous Angiosarcoma Incidencehttps://practicaldermatology.com/news/link-between-uv-exposure-and-cutaneous-angiosarcoma-incidence/2467139/Ambient ultraviolet radiation (UVR) was associated with a higher incidence of cutaneous angiosarcoma (cAS), an aggressive lymphatic/vascular endothelial-based cancer. Researchers publishing the findings in a research letter in Journal of the American Academy of Dermatology (JAAD)<
- Evaxion’s AI-Powered Cancer Vaccine Demonstrates High Response in Early Studyhttps://practicaldermatology.com/news/evaxions-ai-powered-cancer-vaccine-demonstrates-high-efficacy-in-early-study/2467073/Evaxion Biotech A/S, a firm specializing in AI-driven immunology vaccines, recently published data from its Phase 1 dose escalation study of the EVX-01 personalized cancer vaccine for metastatic melanoma showing almost 70% clinical response from patients. The study, published in the J
- Sustained Efficacy Following Treatment With Lebrikizumabhttps://practicaldermatology.com/news/sustained-efficacy-following-treatment-lebrikizumab/2467017/A subset of moderate-to-severe atopic dermatitis (AD) patients who were randomly withdrawn from lebrikizumab maintained a stable EASI 90 response up to Week 52 with negligible remaining lebrikizumab serum concentrations, according to research presented at the Revolutionizing Atopic Dermatitis (RA
- INTEGUMENT-OLE: Efficacy and Safety of Roflumilast Cream 0.15% in AD Maintained to 56 Weekshttps://practicaldermatology.com/news/integument-ole-efficacy-and-safety-roflumilast-cream-ad-maintained-56-weeks/2467010/Results from the INTEGUMENT-OLE long-term study suggested that roflumilast cream 0.15% for the treatment of atopic dermatitis (AD) is effective and well-tolerated over a treatment period of up to 56 weeks in adults and children aged six years and older. Researchers for the open-label study
- FDA Approves First Eyedrops to Treat Mites Living on Eyelasheshttps://practicaldermatology.com/news/fda-approves-first-eyedrops-treat-mites-living-eyelashes/2466993/FDA Approves First Eyedrops to Treat Mites Living on Eyelashes More than 25 million Americans are living with Demodex blepharitis, an underdiagnosed condition that involves mites living on a person’s eyelashes. Demodex blepharitis has gone underdiagnosed for decades because of a l
- Lebrikizumab Maintains Efficacy Through 52 Weekshttps://practicaldermatology.com/news/lebrikizumab-maintains-efficacy-through-52-weeks/2466977/New data from a pooled analysis of the ADvocate1 and ADvocate2 trials indicates lebrikizumab was efficacious for treating atopic dermatitis (AD) over a year-long period. “Lebrikizumab demonstrated significant improvement versus placebo for measures of skin clearance and patient reported ou